Table 2.
Pharmacogenetic variant association of antiplatelet drugs.
| GENE | Ref SNP (rs) number | Association | Condition | Population | References |
|---|---|---|---|---|---|
| CYP3A4 | rs56324128 | Genotype CC is associated with reduced levels of ticagrelor compared to genotype CT. | ACS | European | (101) |
| SLCO1B1 | rs113681054 | Allele C in comparison with allele T is associated with elevated ticagrelor levels. | ACS | European | (101) |
| rs4149056 | Allele T compared to allele C is associated with reduced levels of ticagrelor. | ACS | European | (101) | |
| CYP3A43 | rs62471956 | Allele G is associated with reduced levels of ticagrelor as compared to allele A. | ACS | European | (101) |
| UGT2B7 | rs61361928 | Genotype TT is associated with reduced levels of ticagrelor as compared to genotype CT. | ACS | European | (101) |
| PEAR1 | rs12566888 | Genotype TT is associated with elevated response to ticagrelor as compared to genotype GT. | Healthy individuals | Chinese | (102) |
| rs4661012 | Genotypes GT + TT is associated with reduced response to ticagrelor as compared to genotype GG. | Healthy individuals | Chinese | (102) | |
| rs12041331 | Genotype AA is associated with augmented response to ticagrelor as compared to genotypes AG + GG. | Healthy individuals | Chinese | (102) | |
| rs12041331 | Genotype AA is associated with increased response to ticagrelor as compared to genotype GG. | Healthy individuals | Chinese | (102) | |
| P2RY1 | rs1065776 | Patients with genotype CT may have elevated risk of aspirin-resistant phenotype as compared to patients with genotype TT. | CAD | European | (103) |
| Patients with genotype CT may have reduction in AA-induced platelet aggregation after aspirin treatment as compared to patients with genotype CC. | Healthy individuals | Chinese | (104) | ||
| ITGB3 | rs5918 | Patients with genotype TT may have aspirin-depressed thrombin generation and prolonged bleeding time after aspirin treatment as compared to patients with genotypes CC + CT. | CAD | Poland | (105) |
| Patients with genotypes CC + CT may possess elevated risk of lack of aspirin response as compared to patients with genotype TT. | CAD | Poland | (106) | ||
| Patients with genotype TT may have elevated risk of inadequate inhibition of platelet activity as compared to patients with genotypes CC + CT. | CAD | Tunisian | (107) | ||
| Patients with genotype CT may have reduced aspirin mediated platelet inhibition as compared to patients with genotype TT. | CAD | United States | (89) | ||
| LPA | rs3798220 | Patients with genotype CT may have reduced risk of Myocardial Infarction on aspirin treatment. | Healthy individuals | European | (108) |
| TBXA2R | rs4523 | Patients with genotype AA may have elevated risk of residual platelet reactivity with aspirin treatment as compared to patients with genotypes AG + GG. | Off-pump coronary artery bypass grafting | Chinese | (109) |
| GP6 | rs1613662 | Patients with genotype AG may have elevated risk of non-response to aspirin as compared to patients with genotype GG. | CAD | Finland | (110) |
| GP1BA | rs6065 | Patients with genotypes CT + TT may have elevated response to aspirin in men as compared to patients with genotype CC. | Healthy individuals | Japan | (111) |
| CYP2C19 | rs4244285 | Patients with allele A may possess an elevated risk of platelet reactivity as compared to patients with genotype GG. | ACS | France | (112) |
| Patients with allele A may have increased platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of prasugrel treatment as compared to patients with genotype GG. | ACS | France | (112) | ||
| rs12248560 | Patients with allele T may have reduced platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of prasugrel treatment as compared to patients with genotype CC. | ACS | France | (112) | |
| Patients with allele T may have a reduced rate of high on-treatment platelet reactivity (HTPR) at 1 month of prasugrel treatment as compared to patients with genotype CC. | ACS | France | (112) | ||
| Patients with allele T may possess escalated rate of hyper-response at 1 month of prasugrel treatment as compared to patients with genotype CC. | ACS | France | (112) | ||
| PEAR1 | rs41273215 | Patients with genotype TT may have reduced levels of inhibition of ADP-induced platelet aggregation compared to patients with genotypes CC + CT. | Healthy individuals | Chinese | (113) |
| rs3737224 | Patients with genotype TT may have reduced levels of inhibition of ADP-induced platelet aggregation compared to patients with genotypes CC + CT. | Healthy individuals | Chinese | (113) | |
| rs77235035 | Patients with genotype AA may have reduced levels of inhibition of ADP-induced platelet aggregation as compared to patients with genotypes AC + CC. | Healthy individuals | Chinese | (113) | |
| rs822442 | Patients with genotype AA are associated with reduced levels of inhibition of ADP-induced platelet aggregation as compared to patients with genotypes AC + CC. | Healthy individuals | Chinese | (113) | |
| rs822441 | Patients with genotype CC are associated with reduced levels of inhibition of ADP-induced platelet aggregation as compared to patients with genotypes CG + GG. | Healthy individuals | Chinese | (113) | |
| rs12407843 | Patients with genotype AA are associated with reduced inhibition of ADP-induced platelet aggregation as compared to patients with genotypes AG + GG. | Healthy individuals | Chinese | (113) |
CYP3A4, Cytochrome P450 Family 3 Subfamily A Member 4; SLCO1B1, Solute Carrier Organic Anion Transporter Family Member 1B1; CYP3A43, Cytochrome P450 Family 3 Subfamily A Member 43; UGT2B7, UDP Glucuronosyltransferase Family 2 Member B7; P2RY1, Purinergic Receptor P2Y1; ITGB3, Integrin Subunit Beta 3; LPA, Lipoprotein(A); TBXA2R, Thromboxane A2 Receptor; GP6, Glycoprotein VI Platelet; GP1BA, Glycoprotein Ib Platelet Subunit Alpha; CYP2C19, Cytochrome P450 Family 2 Subfamily C Member 19; PEAR1, Platelet Endothelial Aggregation Receptor 1.